<DOC>
	<DOCNO>NCT00962975</DOCNO>
	<brief_summary>In open-label multicenter study long-term effect Pegasys monotherapy pharmacodynamic HBV-related marker investigate patient chronic hepatitis B . Eligible patient complete treatment another donor protocol ( e.g . PP22512 ) receive Pegasys appropriate dose base standard care ( 180mcg sc weekly ) 48 week . Target sample size &lt; 100 .</brief_summary>
	<brief_title>A Study Pegasys Monotherapy Patients With Chronic Hepatitis B Who Have Participated Previous Studies</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>adult patient &gt; /=18 year age previous participation donor protocol chronic hepatitis B antiHBV treatment completion previous donor protocol female patient female partner male patient must use least two method contraception 28 day completion study hepatic decompensation ( ChildPugh class B C ) antiviral , antineoplastic immunomodulatory treatment evidence alcohol and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>